Related references
Note: Only part of the references are listed.Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation
Mika Kamata-Sakurai et al.
CANCER DISCOVERY (2021)
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
Dimitris Skokos et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Chimeric antigen receptor signaling: Functional consequences and design implications
S. E. Lindner et al.
SCIENCE ADVANCES (2020)
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
Joseph Kauer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade
Rachael M. Zemek et al.
NATURE PROTOCOLS (2020)
Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy
Wei Wu et al.
CELL (2020)
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity
Mauro Castellarin et al.
JCI INSIGHT (2020)
Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
Janelle C. Waite et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Trispecific antibodies take to the clinic
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2020)
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
Iraj Hosseini et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2020)
Engineering better chimeric antigen receptor T cells
Hao Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Structure, Function, and Therapeutic Use of IgM Antibodies
Bruce A. Keyt et al.
ANTIBODIES (2020)
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
Martin Hutchings et al.
BLOOD (2020)
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Karin Staflin et al.
JCI INSIGHT (2020)
COBRA (TM): a highly potent conditionally active T cell engager engineered for the treatment of solid tumors
Anand Panchal et al.
MABS (2020)
Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade
Chien-Chun Steven Pai et al.
IMMUNITY (2019)
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma
Elizabeth J. Davis et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Nathan D. Trinklein et al.
MABS (2019)
Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
Horst-Dieter Hummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy.
Suman Paul et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity
Ji Li et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Katsiaryna Marhelava et al.
CANCERS (2019)
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Rajat Bannerji et al.
BLOOD (2019)
CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory
Hreinn Benonisson et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Wouter Scheper et al.
NATURE MEDICINE (2019)
Recent advances on blinatumomab for acute lymphoblastic leukemia
Juanjuan Zhao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
William R. Strohl et al.
ANTIBODIES (2019)
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Richard W. Joseph et al.
CLINICAL CANCER RESEARCH (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model
Danielle Mandikian et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
E. Mejstrikova et al.
BLOOD CANCER JOURNAL (2017)
Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
A. Trivedi et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Kristin G. Anderson et al.
CANCER CELL (2017)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Laurent Dercle et al.
EUROPEAN JOURNAL OF CANCER (2016)
CD28 Costimulation: From Mechanism to Therapy
Jonathan H. Esensten et al.
IMMUNITY (2016)
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity
Ming-Ru Wu et al.
JOURNAL OF IMMUNOLOGY (2015)
ImmTACs for targeted cancer therapy: Why, what, how, and which
Joanne Oates et al.
MOLECULAR IMMUNOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
Feng Yu et al.
MOLECULAR THERAPY (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer
Vladimir N. Podust et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Luc R. Desnoyers et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
Anja Feldmann et al.
JOURNAL OF IMMUNOLOGY (2012)
Immunotherapy of Cancer with 4-1BB
Dass S. Vinay et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Catumaxomab Clinical development and future directions
Rolf Linke et al.
MABS (2010)
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
Sanjiv S. Agarwala et al.
EUROPEAN JOURNAL OF CANCER (2009)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
Christian Brandl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
Ganesh Suntharalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-XL and c-FLIPshort via phosphatidylinositol 3-kinase and AKT/protein kinase B
L Stärck et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Ligation of CD 137 receptor prevents and reverses established anergy of CD8(+) cytolytic T lymphocytes in vivo
RA Wilcox et al.
BLOOD (2004)
Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction:: Manifestation of a dual activation threshold
M Faroudi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1
HW Lee et al.
JOURNAL OF IMMUNOLOGY (2002)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Eradication of established tumors by CD8+ T cell adoptive immunotherapy
HL Hanson et al.
IMMUNITY (2000)
Share Paper
